Jazz Pharmaceuticals, a developer of treatments for various neurological and psychiatric disorders, released the revised range on Thursday morning. Its anticipated IPO price is now $20-$21, down from its prior forecast of $24-$26, an 18% decline from the midpoint. Morgan Stanley and Lehman Brothers are joint bookrunners on the deal.
